Involved-Field Radiotherapy for Advanced Hodgkin's Lymphoma

Aleman, Berthe M.P.; Raemaekers, John M.M.; Tirelli, Umberto; Bortolus, Roberto; van 't Veer, Mars B.; Lybeert, Marnix L.M.; Keuning, Jo J.; Carde, Patrice; Girinsky, Théodore; van der Maazen, Richard W.M.; Tomšič, Radka; Vovk, Marjeta; van Hoof, Achilles; Demeestere, Geertrui; Lugtenburg, Pieternella J.; Thomas, José; Schroyens, Wilfried; De Boeck, Koenraad; Baars, Johanna W.; Kluin-Nelemans, Johanna C.
June 2003
New England Journal of Medicine;6/12/2003, Vol. 348 Issue 24, p2396
Academic Journal
Background: The use of involved-field radiotherapy after chemotherapy for advanced Hodgkin's lymphoma is controversial. Methods: We randomly assigned patients with previously untreated stage III or IV Hodgkin's lymphoma who were in complete remission after hybrid chemotherapy with mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (MOPP-ABV) to receive either no further treatment or involved-field radiotherapy. Radiotherapy consisted of 24 Gy to all initially involved nodal areas and 16 to 24 Gy to all initially involved extranodal sites. Patients in partial remission were treated with 30 Gy to nodal areas and 18 to 24 Gy to extranodal sites. Results: Of 739 patients, 421 had a complete remission; 161 of these patients were assigned to no further treatment, and 172 to involved-field radiotherapy. The median follow-up was 79 months. The five-year event-free survival rate was 84 percent in the group that did not receive radiotherapy and 79 percent in the group that received involved-field radiotherapy (P=0.35). The five-year overall survival rates were 91 and 85 percent, respectively (P=0.07). Among the 250 patients in partial remission after chemotherapy, the five-year event-free and overall survival rates were 79 and 87 percent, respectively. Conclusions: Involved-field radiotherapy did not improve the outcome in patients with advanced-stage Hodgkin's lymphoma who had a complete remission after MOPP-ABV chemotherapy. Radiotherapy may benefit patients with a partial response after chemotherapy. N Engl J Med 2003;348:2396-406.


Related Articles

  • Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease. Diehl, Volker; Franklin, Jeremy; Pfreundschuh, Michael; Lathan, Bernd; Paulus, Ursula; Hasenclever, Dirk; Tesch, Hans; Herrmann, Richard; Dorken, Bernd; Müller-Hermelink, Hans-Konrad; Dühmke, Eckhardt; Loeffler, Markus // New England Journal of Medicine;6/12/2003, Vol. 348 Issue 24, p2386 

    Background: Faced with unsatisfactory results of treatment for advanced Hodgkin's disease, we investigated three combinations of chemotherapy. Methods: From 1993 to 1998, 1201 eligible patients 15 to 65 years of age who had newly diagnosed Hodgkin's disease in unfavorable stage IIB or IIIA or...

  • Research & Markets: Brentuximab Vedotin - First Treatment Option for Relapsed Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (Subset of Non-Hodgkin Lymphoma).  // Biomedical Market Newsletter;8/23/2011, Vol. 21, p77 

    The article discusses the need for drugs with enhanced toxicity and efficacy in treating Hodgkin and non-Hodgkin lymphoma. It says that the relapse rate for Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL) patients are 30% and 50%. It mentions the report "Brentuximab Vedotin: First...

  • Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. DeVita, Vincent T.; Simon, Richard M.; Hubbard, Susan M.; Young, Robert C.; Berard, Costan W.; Moxley, John H.; Frei, Emil; Carbone, Paul P.; Canellos, George P.; DeVita, V T Jr; Simon, R M; Hubbard, S M; Young, R C; Berard, C W; Moxley, J H 3rd; Frei, E 3rd; Carbone, P P; Canellos, G P // Annals of Internal Medicine;May80, Vol. 92 Issue 5, p587 

    The results of treatment of 198 patients with Hodgkin's disease with MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) were analyzed. Eighty percent attained complete remission, and 68% of patients achieving a complete remission have remained disease free beyond 10 years from the...

  • The cure of disseminated Hodgkin's disease: prospects and problems. Streuli, Rolf A.; Ultmann, John E.; Streuli, R A; Ultmann, J E // Annals of Internal Medicine;May80, Vol. 92 Issue 5, p693 

    Editorial. Discusses prospects and problems in the treatment of disseminated Hodgkin's disease. Use of the mechlorethamine, vincristine, procarbazine and prednisone (MOPP) program in the treatment of the disease; Long-term complications after MOPP treatment of patients; Drug therapies proposed...

  • Treatment decisions in a man with Hodgkin lymphoma and Guillian-Barré syndrome: a case report. Hughes, Caren L.; Yorio, Jeffrey T.; Kovitz, Craig; Oki, Yasuhiro // Journal of Medical Case Reports;2014, Vol. 8 Issue 1, p567 

    Introduction Guillain-Barre syndrome, or acute inflammatory demyelinating polyneuropathy, has been described in the presence of malignancies such as lymphoma. Guillain-Barre syndrome/acute inflammatory demyelinating polyneuropathy causes paresthesias and weakness, which can make the treatment of...

  • Antineoplastics.  // Reactions Weekly;10/21/2006, Issue 1124, p6 

    The article presents the case of a 31-year-old man who developed telangiectasia after receiving antineoplastic therapy with doxorubicin, bleomycin, vinblastine and dacarbazine for Hodgkin's disease. It references a study by M. Rodríguez-Martín et al, published in the September 2006 issue...

  • Impact of first- and second-line treatment for Hodgkin’s lymphoma on the incidence of AML/MDS and NHL—experience of the German Hodgkin’s Lymphoma Study Group analyzed by a parametric model of carcinogenesis. Scholz, M.; Engert, A.; Franklin, J.; Josting, A.; Diehl, V.; Hasenclever, D.; Loeffler, M. // Annals of Oncology;Mar2011, Vol. 22 Issue 3, p681 

    Background: Using a parametric carcinogenesis model, we disentangle the superimposing effects of primary and relapse therapies of Hodgkin's disease on secondary neoplasias.Patients and methods: We analyze eight randomized trials of the German Hodgkin's lymphoma study group [5357 individuals, 67...

  • Cancer Chemotherapy Update. Solimando Jr., Dominic A.; Waddell, Aubrey // Hospital Pharmacy;Oct2009, Vol. 44 Issue 10, p858 

    The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparing, dispensing, and administering antineoplastic therapy and to the agents, commercially available and...

  • Bleomycin, Adriamycin, Cyclophosphamide, Vincristine, and Prednisone (BACOP) Combination Chemotherapy in the Treatment of Advanced Diffuse Histiocytic Lymphoma. Schein, Philip S.; DeVita, Vincent T.; Hubbard, Susan; Chabner, Bruce A.; Canellos, George P.; Berard, Costan; Young, Robert C. // Annals of Internal Medicine;Oct76, Vol. 85 Issue 4, p417 

    Provides information on a study that used a myelosuppressive phase consisting of adriamycin, cyclophosphamide and vincristine followed by the nonmyelosuppressive agents bleomycin and prednisone for the treatment of advanced diffuse histiocytic lymphoma. Methodology of the study; Results and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics